Align Summit: Toronto based HDAX Therapeutics believes there are many indications to tackle with its dual binding approach to HDAC6
Oct 7, 2025
05:20
forum Ask episode
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
Co-Founder & CEO Nabanita Nawar describes the need for tackle HDAC6 with better chemistry. Plus, what it is like being a biotech startup in Canada today.